Other Issues

Browse Other Issues Content

This white paper provides guidance for the evaluation and reporting of impurities in OTC monograph drug products formulated as topicals and topical rinses. This document serves as CHPA's member company consensus on this complex issue.

Current good manufacturing practices establish uniform standards to ensure quality throughout the manufacturing, packaging, labeling, and holding of OTC medicines and dietary supplement products.

CHPA supports the regulatory authorities governing dietary supplement manufacturing, labeling, and marketing and works to ensure the availability of safe dietary supplements.

CHPA is uniquely positioned to provide access to OTC medicines and dietary supplements in nearly every category that can be donated and customized to the needs of underserved communities. Our product donation initiative is an ongoing effort to support these communities. So far, CHPA member companies have donated 70,000 products to people in need.

CHPA opposes mandatory manufacturer-funded drug take-back programs as they threaten the affordability of OTC medications that consumers rely on as the first line of defense against common ailments.

CHPA encourages state and local lawmakers to refrain from creating new legislation addressing green chemistry in pharmaceuticals, and instead rely on the rigorous guidelines and standards already implemented at the federal level by agencies like the FDA.

Find frequently asked questions about the Standardized Information on Dietary Ingredients (SIDI).

Though rising PFAS levels prompt important health questions that must be monitored, restrictions should remain grounded in conclusive toxicology to avoid reactionary bans on safe modern alternatives — as inconsistent standards across 50 individual states would only stifle healthcare advancement.

Filter Results